Saudi newborn screening will detect 25-35 infantile Pompe cases yearly, while late-onset patients are still found at 55-65% FVC.
Pompe disease incidence in the GCC runs 1 in 20,000 to 30,000 live births versus roughly 1 in 40,000 globally, elevated by consanguinity; infantile-onset Pompe represents a larger proportion of GCC cases than in global series, consistent with the region's consanguinity pattern. Saudi Arabia added Pompe disease, via a GAA dried-blood-spot assay, to its national newborn screening programme in 2021, with an expected 25 to 35 combined GCC infantile-onset detections annually. The KFSH&RC metabolic genetics programme has treated approximately 120 Pompe patients of all subtypes over 15 years, the region's largest single-centre experience.
Late-onset Pompe disease follows a very different path: GCC patients typically present at age 20 to 40 with progressive proximal myopathy or respiratory decline, and diagnosis often comes only after multiple rheumatology or neurology assessments have first considered, and excluded, limb-girdle muscular dystrophy. Baseline forced vital capacity at diagnosis is estimated at 55% to 65% predicted, indicating advanced disease by the time enzyme assay and genetic confirmation finally occur. Enzyme replacement therapy requires specialist infusion capacity available at only 6 to 8 centres across all six GCC countries, and patients outside these cities travel 100 to 300km for biweekly infusions, though KFSH&RC piloted a home infusion programme in 2022.
Late-onset Pompe hides behind a limb-girdle muscular dystrophy diagnosis for years.
Five questions this report answers:
Q1 - How is Saudi Arabia's 2021 newborn screening expansion changing the infantile-onset diagnosed population?
Q2 - Why do late-onset Pompe patients pass through a limb-girdle muscular dystrophy detour?
Q3 - Which GCC metabolic centres have ERT infusion capacity, and what does that gap mean for access?
Q4 - How do newborn screening and diagnostic delay reshape the addressable GCC Pompe market?
Q5 - Why does GCC Pompe disease incidence run 33-100% above the global rate?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#PompeDisease #RareDisease #NewbornScreening #GCCHealthcare #DiseaseLandscape
Live report page: https://axlrx.ai/pompe-disease/gcc/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
PNH's 800-1,200 patient EVH subpopulation, not the full 15,000-20,000 prevalence estimate, defines the complement-inhibitor era opportunity.
PNH is a clonal haematopoietic stem cell disorder caused by somatic PIG-A mutation, leading to GPI-anchor deficiency and complement-mediated red blood cell lysis. US prevalence is estimated at 15,000 to 20,000 patients, median age 35, with equal sex distribution. The disease spans three clinically and commercially distinct axes, haemolysis-dominant, aplasia-dominant, and thrombotic PNH, each requiring different treatment approaches and commercial micro-segmentation rather than a single undifferentiated patient count.
Mean diagnostic delay is 2.4 years, driven by misdiagnosis as autoimmune haemolytic anaemia, aplastic anaemia, or MDS. Approximately 15 to 20% of aplastic anaemia patients harbour PNH clones, forming the largest undiagnosed patient pool. Anti-C5 therapy has dramatically reduced thrombotic mortality, but 800 to 1,200 patients with extra-vascular haemolysis, persistent anaemia despite IV complement inhibition, define the residual unmet need and the commercial rationale for proximal complement inhibitors such as iptacopan.
The EVH subpopulation, not total prevalence, is where the commercial case actually lives.
Five questions this report answers:
Q1 - What is the size and clinical characterisation of the EVH-dominant US PNH subpopulation?
Q2 - What is the diagnostic pathway for PNH, and where are the largest undiagnosed patient pools?
Q3 - How does the PNH disease spectrum drive different treatment decisions and commercial micro-segmentation?
Q4 - Which US PNH subpopulations represent the greatest unmet commercial need today?
Q5 - What share of aplastic anaemia patients actually harbour an undiagnosed PNH clone?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#PNH #US #RareDisease #DiseaseLandscape #ComplementInhibitor #Hematology
Live report page: https://axlrx.ai/pnh/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
UK PNH diagnosis takes just 6-12 months through Leeds, yet 30% of the ~600 tracked patients also have aplastic anaemia.
PNH is a clonal haematopoietic stem cell disorder caused by somatic PIG-A mutation, producing GPI-anchor deficiency and complement-mediated red blood cell lysis. The Leeds National PNH Service runs the UK's single national registry: approximately 600 patients on complement inhibitor therapy, plus 100 to 150 additional patients with small PNH clones monitored without treatment. Annual new UK diagnoses run 50 to 70, with a median age at diagnosis of 38 to 42 years and an equal gender distribution across the tracked cohort.
UK PNH survival on complement inhibitor therapy now approaches that of the general population, a landmark outcome for a historically fatal disease. Around 30% of UK PNH patients have concurrent aplastic anaemia features requiring dual management: complement inhibitor alongside immunosuppressive therapy, eltrombopag, or a bone marrow transplant discussion, coordinated through the Leeds multidisciplinary service and 15 JACIE-accredited NHS BMT centres across the country.
Nearly a third of UK PNH patients need dual disease management.
Five questions this report answers:
Q1 - What is the size of the NHS-commissioned PNH population against the pending iptacopan decision?
Q2 - Why does the UK achieve a materially shorter PNH time-to-diagnosis than other markets?
Q3 - How does the 30% PNH-aplasia overlap population get managed within the NHS?
Q4 - What does the pending iptacopan NICE decision mean for UK PNH access?
Q5 - How many UK PNH patients are monitored on the Leeds registry without active treatment?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#PNH #NHS #NICE #RareDisease #UKHealthcare #DiseaseLandscape
Live report page: https://axlrx.ai/pnh/uk/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
Germany's own DGHO guideline admits it has no national PNH data, borrowing 16 cases per million from UK and France.
PNH is a clonal haematopoietic stem cell disorder caused by somatic PIG-A mutation, producing GPI-anchor deficiency and complement-mediated red blood cell lysis. Diagnosis requires GPI-anchor flow cytometry showing deficient or reduced expression of at least two GPI-anchored markers across at least two cell lineages, typically granulocytes and reticulocytes. In Germany, that testing and the resulting patient population concentrate almost entirely at two institutions: the German PNH-Register, housed at Ulm's Institute for Clinical Transfusion Medicine and Immunogenetics, and the West German Cancer Center at University Hospital Essen. Both feed patients into the International PNH Registry, the same dataset underpinning the long-term ravulizumab and eculizumab outcomes literature.
The DGHO's own Onkopedia clinical guideline, the reference document German haematologists use, states directly that Germany-specific prevalence and incidence figures do not exist. In their place, it extrapolates an estimated 16 cases per million and 1.3 new diagnoses per million annually from British and French registry data. That borrowed-estimate approach has a direct commercial consequence: any epidemiology-based market sizing for a new PNH therapy launching in Germany inherits the uncertainty of a foreign-registry extrapolation rather than a domestic count, and the two-centre referral concentration means patient-finding runs through a narrower institutional funnel than in markets with broader registry infrastructure.
Germany's own guideline runs on borrowed numbers, not a domestic patient count.
Five questions this report answers:
Q1 - Why does Germany's own clinical guideline say national PNH prevalence data doesn't exist?
Q2 - Where does PNH diagnosis and care concentrate in Germany, and what does that mean for patient-finding?
Q3 - What diagnostic criteria confirm a PNH case in the German clinical pathway?
Q4 - What prevalence and incidence estimate does the DGHO Onkopedia guideline borrow from UK and France?
Q5 - Which two German institutions feed patient data into the International PNH Registry?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#PNH #Germany #DGHO #RareDisease #DiseaseLandscape #HematologyMarket
Live report page: https://axlrx.ai/pnh/germany/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
Fewer than 15 GCC labs run FLAER flow cytometry, holding confirmed PNH cases below 400 against 2,000-3,000 estimated patients.
Paroxysmal nocturnal hemoglobinuria is a clonal haematopoietic stem cell disorder caused by an acquired somatic PIG-A mutation, producing GPI-anchor-deficient blood cells vulnerable to complement-mediated lysis. Across the GCC, an estimated 2,000 to 3,000 patients carry PNH clones large enough to be clinically significant, but only around 400 are confirmed in NPHC and specialist haematology registries. The gap reflects both near-zero community disease awareness outside haematology and a consanguinity rate of 25% to 50% across Gulf populations, which raises the likelihood that a somatic PIG-A mutation acquires clinical significance against a background of higher underlying immune and clonal stress.
The standard PNH diagnostic panel, FLAER flow cytometry plus CD55/CD59, is available at fewer than 15 laboratories across the six GCC states. Most peripheral hospitals either refer samples internationally or fall back on CD55/CD59-only testing, which carries a 20% to 30% false-negative rate for small-clone PNH. Confirmed diagnosis concentrates at specialist centres such as KFSH&RC, which anchors the region's largest published PNH case series. Median time to diagnosis for symptomatic GCC patients runs two to four years, and disease often surfaces first as Budd-Chiari syndrome or aplastic anaemia; PNH-aplasia overlap accounts for 25% to 30% of GCC PNH cases against roughly 15% globally.
A lab-access gap, not disease rarity, hides most GCC PNH patients.
Five questions this report answers:
Q1 - What is the true size of the undiagnosed GCC PNH population, and where does it concentrate?
Q2 - Which GCC laboratories run FLAER flow cytometry, and what does that mean for time-to-treatment?
Q3 - What does compassionate-access-only status mean for near-term GCC uptake of iptacopan?
Q4 - What diagnostic and access barriers define the addressable GCC PNH market?
Q5 - Why does PNH often first present as Budd-Chiari syndrome or aplastic anaemia in the GCC?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#PNH #RareDisease #GCCHealthcare #Haematology #DiseaseLandscape #SFDA
Live report page: https://axlrx.ai/pnh/gcc/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
France's own hospitalization database puts 2022 PNH prevalence near 1 in 94,000, below Germany's borrowed 16-per-million figure.
A 2025 real-world study drawn from France's national hospitalization database, PMSI, accessed via the CASD secure data platform and funded by Roche France, identified 897 PNH patients between 2018 and 2022, with the annual count rising from 581 to 725 and roughly 100 newly diagnosed patients added each year. That translates to a 2022 prevalence near 1 in 94,000, below the 1-in-70,000-to-80,000 range Orphanet and France's national rare disease plan had assumed. The same cohort shows 55.3% of patients on a C5 inhibitor, with eculizumab accounting for 89.9% of new treatment starts and ravulizumab 10.1%. This is one of the few PNH cohorts in Europe built entirely from administrative hospital records rather than a clinician-reported registry.
For commercial teams, the discrepancy is the finding: Germany's DGHO Onkopedia guideline borrows a PNH prevalence of 16 cases per million from UK and French registries, yet France's own current hospital-database figure, 897 patients against a population of roughly 68 million, near 10.6 per million, comes in lower. France also runs diagnostic infrastructure other countries reference, a French National Observatory of PNH Clones sitting on an inter-laboratory flow-cytometry harmonization programme spanning more than 50 French-speaking centres since 2010. A market-sizing exercise anchored only on the literature-cited 16-per-million figure will overstate the addressable French population relative to what the country's own administrative data now shows.
France's own data undercuts the very prevalence figure Germany borrows from it.
Five questions this report answers:
Q1 - How big is France's treatable PNH population versus the literature estimate used elsewhere in Europe?
Q2 - Which centres actually see and diagnose PNH patients across France?
Q3 - How long does it take a French patient to reach a confirmed PNH diagnosis?
Q4 - What share of France's PNH cohort is on eculizumab versus ravulizumab today?
Q5 - How many French-speaking centres participate in the flow-cytometry harmonization programme behind France's PNH Observatory?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#PNH #France #PMSI #RareDisease #DiseaseLandscape #HematologyMarket
Live report page: https://axlrx.ai/pnh/france/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
41.9% of US adults meet the obesity threshold, but comorbidity segments, not the headline count, decide who gets covered.
Obesity is a chronic, relapsing metabolic disease defined by a body-mass index of 30 or greater. CDC NHANES data put US adult obesity prevalence at 41.9%, roughly 100 million adults, with severe obesity (BMI 40 or above) affecting 9.2%, about 22 million people. The most recent NHANES cycle shows age-adjusted obesity at 40.3% and severe obesity at 9.7%, up from 30.5% in 1999-2000. The disease stratifies into Class I (30-34.9), Class II (35-39.9), and Class III or severe (40 and above), each carrying a different comorbidity load and a different treatment and coverage rationale.
The clinical case for treatment now rests on outcomes, not weight alone. Two GLP-1 agents dominate: semaglutide 2.4mg (Wegovy, Novo Nordisk) delivered 15.3% weight loss in the STEP 1 trial, while tirzepatide (Zepbound, Eli Lilly) delivered 20.9% at its 15mg dose in SURMOUNT-1, a clear head-to-head efficacy gap. The SELECT trial then showed semaglutide cut major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease but without diabetes, converting obesity from a cosmetic indication into a cardiovascular one. That evidence reframes the addressable population around comorbidity-defined segments that payers and Medicare will actually fund.
BMI alone no longer decides who gets treated or who gets paid for.
Five questions this report answers:
Q1 - How does the US obesity population stratify by BMI class and comorbidity?
Q2 - How does GLP-1 head-to-head efficacy in obesity map to patient segmentation?
Q3 - How large is the comorbidity-linked population anchoring obesity coverage, CVD and type 2 diabetes?
Q4 - How many US adults have obesity, and how is severe obesity defined?
Q5 - Which obesity segment opened Medicare coverage, and why does comorbidity outweigh BMI alone?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#Obesity #GLP1 #Cardiometabolic #USHealthcare #DiseaseLandscape
Live report page: https://axlrx.ai/obesity/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
NSCLC splits into five biomarker-defined segments, and 51% of US patients are diagnosed only after the disease reaches distant stage.
Non-small cell lung cancer is not one disease to size. Adenocarcinoma accounts for roughly 40% of all lung cancers, squamous cell carcinoma for 25 to 30%, and large cell carcinoma for about 10%. Within that histology map sits the segmentation that actually drives treatment: EGFR, ALK, ROS1, KRAS G12C, and PD-L1 expression tier, each carrying a different first-line standard of care, and sizing the wrong one is the most common pre-launch error. The US will see an estimated 229,410 new lung cancer diagnoses in 2026, and non-small cell histology accounts for roughly 85% of them.
Fifty-one percent of cases present at distant stage against just 24% localized, based on SEER 2016-2022 diagnosis data, and the biomarker-driven segment map only helps a patient whose disease is caught before it reaches that point. EGFR, ALK, KRAS G12C, and PD-L1 prevalence vary meaningfully across US and North American cohorts, and the diagnosis-to-treatment pathway loses patients between tissue-NGS or liquid-biopsy testing and the point first-line therapy actually starts, with turnaround time and guideline-complete testing rate the two levers that matter most for commercial modelling.
Sizing the wrong biomarker segment is the most common pre-launch NSCLC error.
Five questions this report answers:
Q1 - How does NSCLC segment by histology and actionable biomarker, and what governs treatment choice in each?
Q2 - How many patients present early enough for that segmentation to matter?
Q3 - What share of NSCLC actually carries each actionable biomarker?
Q4 - Which US centers and trial networks define practice and generate the evidence base?
Q5 - Where does the diagnosis-to-treatment pathway lose patients, and how fast does it move?
Share your commercial question with us. We'll align on scope — then build the right intelligence around it.
→ moatrx.com/axlrx.html
#NSCLC #LungCancer #Biomarkers #PrecisionOncology #DiseaseLandscape #USMarket
Live report page: https://axlrx.ai/nsclc/disease-landscape/
Thanks & Regards,
Mike || Global Pharma Commercial Marketing Head
Email- hello@axlrx.ai
Web- https://axlrx.ai/
